Skip to main content

IBA和SCK CEN成立合资公司Pantera 合作生产锕-225

IBA和SCK CEN成立合资公司Pantera 合作生产锕-225

Thursday, September 22, 2022 - 7:53

<p><span><span><span><span><strong><span lang="ZH-CN"><span>比利时新鲁汶</span></span></strong><strong><span><span>2022</span></span></strong><strong><span lang="ZH-CN"><span>年</span></span></strong><strong><span><span>9</span></span></strong><strong><span lang="ZH-CN"><span>月</span></span></strong><strong><span><span>22</span></span></strong><strong><span lang="ZH-CN"><span>日</span></span></strong><strong><span><span> - IBA(Ion Beam Applications S.A.,</span></span></strong><strong><span lang="ZH-CN"><span>泛欧交易所上市公司</span></span></strong><strong><span lang="ZH-CN"><span>),</span></span></strong><strong><span lang="ZH-CN"><span>粒子加速器技术的世界领先者之一</span></span></strong><strong><span lang="ZH-CN"><span>,</span></span></strong><strong><span lang="ZH-CN"><span>与比利时核能研究中心</span></span></strong><strong><span><span>SCK</span></span></strong><strong><span><span> </span></span></strong><strong><span><span>CEN</span></span></strong><strong><span lang="ZH-CN"><span>于今日宣布双方合资公司名称为</span></span></strong><strong><span lang="ZH-CN"><span>:</span></span></strong><strong><span><span>Pantera SA/NV,</span></span></strong><strong><span lang="ZH-CN"><span>双方相信该公司的成立将为癌症患者带来新的希望。正如研发战略合作公告中所示,这家新公司的目标是确保锕</span></span></strong><strong><span lang="EN-US"><span>-225</span></span></strong><strong><span lang="ZH-CN"><span>(</span></span></strong><strong><span lang="EN-US"><span>Ac-225</span></span></strong><strong><span lang="ZH-CN"><span>)的大规模生产,锕</span></span></strong><strong><span lang="EN-US"><span>-225</span></span></strong><strong><span lang="ZH-CN"><span>是最有希望用于对抗癌症的</span></span></strong><strong><span lang="EN-US"><span>α</span></span></strong><strong><span lang="ZH-CN"><span>放射性同位素之一。通过实现这种同位素的大规模生产,</span></span></strong><strong><span lang="EN-US"><span>Pantera</span></span></strong><strong><span lang="ZH-CN"><span>的最终目标在于提高基于锕</span></span></strong><strong><span lang="EN-US"><span>-225</span></span></strong><strong><span lang="ZH-CN"><span>未来创新癌症疗法的可及性。</span></span></strong></span></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><span><span><span lang="EN-US"><span><span>IBA</span></span></span><span lang="ZH-CN"><span><span>和</span></span></span><span lang="EN-US"><span><span>SCK</span></span></span><span lang="EN-US"><span><span> </span></span></span><span lang="EN-US"><span><span>CEN</span></span></span><span lang="ZH-CN"><span><span>去年进行了广泛而全面的研发合作</span></span></span><span lang="ZH-CN"><span><span>,致力于大批量生产锕</span></span></span><span lang="EN-US"><span><span>-225</span></span></span><span lang="ZH-CN"><span><span>,双方在各自专业领域上的互补性在合作中得以体现。</span></span></span><span lang="EN-US"><span><span>Pantera</span></span></span><span lang="ZH-CN"><span><span>目前正在完成技术可行性研究</span></span></span><span lang="ZH-CN"><span><span>,之后将开始对其位于比利时莫尔的第一家工厂进行最终设计和建造。预计将于</span></span></span><span lang="EN-US"><span><span>2024</span></span></span><span lang="ZH-CN"><span><span>年动工,并于</span></span></span><span lang="EN-US"><span><span>2027</span></span></span><span lang="ZH-CN"><span><span>年投入生产。</span></span></span></span></span></span></span></span></p> <p><span><span><span><span><span lang="EN-US"><span><span>SCK </span></span></span><span lang="EN-US"><span><span>CEN</span></span></span><span lang="ZH-CN"><span><span>核能研究中心前院长</span></span></span><span lang="EN-US"><span><span>Seven</span></span></span><span lang="EN-US"><span><span> Van den </span></span></span><span lang="EN-US"><span><span>Berghe</span></span></span><span lang="ZH-CN"><span><span>已被任命为首席执行官</span></span></span><span lang="ZH-CN"><span><span>,</span></span></span><span lang="ZH-CN"><span><span>而</span></span></span><span lang="EN-US"><span><span>IBA</span></span></span><span lang="ZH-CN"><span><span>治疗诊断学应用前技术负责人</span></span></span><span lang="EN-US"><span><span>Samy</span></span></span><span lang="EN-US"><span><span> </span></span></span><span lang="EN-US"><span><span>Bertrand</span></span></span><span lang="ZH-CN"><span><span>将担任首席技术官</span></span></span><span lang="ZH-CN"><span><span>。</span></span></span></span></span></span></span></p> <p><span><span><span><span><strong><span lang="EN-US"><span><span>IBA</span></span></span></strong><strong><span lang="ZH-CN"><span><span>放射制药解决方案总裁兼</span></span></span></strong><strong><span lang="EN-US"><span><span>Pantera</span></span></span></strong><strong><span lang="ZH-CN"><span><span>董事会主席</span></span></span></strong><strong><span lang="EN-US"><span><span>Bruno</span></span></span></strong><strong><span lang="EN-US"><span><span> </span></span></span></strong><strong><span lang="EN-US"><span><span>Scutnaire</span></span></span></strong><strong><span lang="ZH-CN"><span><span>表示</span></span></span></strong><strong><span lang="ZH-CN"><span><span>:</span></span></span></strong><em><span lang="EN-US"><span><span>“</span></span></span></em><em><span lang="ZH-CN"><span><span>锕</span></span></span></em><em><span lang="EN-US"><span><span>-225</span></span></span></em><em><span lang="ZH-CN"><span><span>为多种癌症的治疗提供了巨大希望,但目前全球范围内可用之材甚少。一旦基于锕</span></span></span></em><em><span lang="EN-US"><span><span>-225</span></span></span></em><em><span lang="ZH-CN"><span><span>的癌症治疗获得批准,</span></span></span></em><em><span lang="EN-US"><span><span>Pantera</span></span></span></em><em><span lang="ZH-CN"><span><span>将专注于让这种具有前景的同位素实现可靠供应。</span></span></span></em><em><span lang="EN-US"><span><span>”</span></span></span></em></span></span></span></span></p> <p><span><span><span><span><strong><span lang="EN-US"><span><span>SCK </span></span></span></strong><strong><span lang="EN-US"><span><span>CEN</span></span></span></strong><strong><span lang="ZH-CN"><span><span>副总干事兼</span></span></span></strong><strong><span lang="EN-US"><span><span> Pantera </span></span></span></strong><strong><span lang="ZH-CN"><span><span>董事会成员</span></span></span></strong><strong><span lang="EN-US"><span><span> Peter Baeten </span></span></span></strong><strong><span lang="ZH-CN"><span><span>评论说:</span></span></span></strong><em><span lang="EN-US"><span><span>“</span></span></span></em><em><span lang="ZH-CN"><span><span>成立</span></span></span></em><em><span lang="EN-US"><span><span>Pantera</span></span></span></em><em><span lang="EN-US"><span><span> </span></span></span></em><em><span lang="ZH-CN"><span><span>是</span></span></span></em><em><span lang="EN-US"><span><span> SCK CEN </span></span></span></em><em><span lang="ZH-CN"><span><span>和</span></span></span></em><em><span lang="EN-US"><span><span> IBA </span></span></span></em><em><span lang="ZH-CN"><span><span>的合理选择,它使得合资企业能够利用双方的创新能力,同时在这个快速发展的领域中,充分利用必要的自主创业速度。</span></span></span></em><em><span lang="EN-US"><span><span>”</span></span></span></em></span></span></span></span></p> <p><span><span><span><span><strong><span lang="ZH-CN"><span><span>被任命为</span></span></span></strong><strong><span lang="EN-US"><span><span> Pantera </span></span></span></strong><strong><span lang="ZH-CN"><span><span>首席执行官的</span></span></span></strong><strong><span lang="EN-US"><span><span> Sven Van den Berghe </span></span></span></strong><strong><span lang="ZH-CN"><span><span>补充说:</span></span></span></strong><em><span lang="EN-US"><span><span>“</span></span></span></em><em><span lang="ZH-CN"><span><span>我为能获得这个帮助</span></span></span></em><em><span lang="EN-US"><span><span> Pantera </span></span></span></em><em><span lang="ZH-CN"><span><span>推进使命前行,通过广泛使用作为新兴放射性药物基础的放射性同位素如锕</span></span></span></em><em><span lang="EN-US"><span><span>-225</span></span></span></em><em><span lang="ZH-CN"><span><span>,为癌症患者带来新希望的机会感到兴奋。</span></span></span></em><em><span lang="EN-US"><span><span>Pantera </span></span></span></em><em><span lang="ZH-CN"><span><span>提供</span></span></span></em><em><span lang="EN-US"><span><span>‘</span></span></span></em><em><span lang="ZH-CN"><span><span>更好地为生存而战</span></span></span></em><em><span lang="EN-US"><span><span>’</span></span></span></em><em><span lang="ZH-CN"><span><span>的机会</span></span></span></em><em><span lang="ZH-CN"><span><span>,有希望带来有效和高效的治疗选择,同时最大限度地提高患者的生活质量,并有可能在未来将生产扩展到其他同位素的生产上。</span></span></span></em><em><span lang="EN-US"><span><span>”</span></span></span></em></span></span></span></span></p> <p><span><span><span><span lang="ZH-CN"><span><span>锕</span></span></span><span lang="EN-US"><span><span>-225</span></span></span><span lang="ZH-CN"><span><span>拥有更加有效治疗癌症的巨大潜力。初步结果表明,用于治疗的放射性同位素可以完全消除癌细胞,而不仅仅是抑制肿瘤生长。复发的风险似乎也降低了。到目前为止,旨在应对高发病率癌症及罕见癌症的广泛调查和大量研究正在进行中,高发病率癌症包括前列腺癌、肺癌、结肠癌、乳腺癌、胰腺癌、血癌(白血病和其他罕见病)和肾癌在内的高发病率癌症,罕见的癌症,如胶质母细胞瘤,这是一种最致命的侵袭性脑癌。</span></span></span></span></span></span></p> <p><span><span><span><span lang="EN-US"><span><span>***</span></span></span><span lang="ZH-CN"><span><span>结束</span></span></span><span lang="EN-US"><span><span>***</span></span></span></span></span></span></p> <p><span><span><span><strong><span lang="ZH-CN"><span>关于</span></span></strong><strong><span lang="EN-US"><span>IBA</span></span></strong></span></span></span></p> <p><span><span><span><span lang="EN-US"><span>IBA</span></span><span lang="ZH-CN"><span>(</span></span><span lang="EN-US"><span>Ion Beam Applications S.A.</span></span><span lang="ZH-CN"><span>)是粒子加速器技术的世界领先者。该公司是质子治疗领域设备和服务的领先供应商之一,被认为是当今更先进的放射治疗形式</span></span><span lang="ZH-CN"><span><span>。</span></span></span><span lang="EN-US"><span><span>IBA </span></span></span><span lang="ZH-CN"><span><span>还是工业灭菌、放射性药物和剂量学领域的领先企业之一。该公司总部位于比利时新鲁汶,在全球拥有约</span></span></span><span lang="EN-US"><span><span>1,600</span></span></span><span lang="ZH-CN"><span><span>名员工。</span></span></span><span lang="EN-US"><span><span>IBA</span></span></span><span lang="ZH-CN"><span><span>是一家通过共益企业</span></span></span><span lang="EN-US"><span><span> (B Corp)</span></span></span><span lang="ZH-CN"><span><span>认证的公司,符合经验证的社会和环境绩效的最高标准。</span></span></span></span></span></span></p> <p><span><span><span><span lang="EN-US"><span><span>IBA</span></span></span><span lang="ZH-CN"><span><span>在泛欧证券交易所</span></span></span><span lang="ZH-CN"><span><span>(</span></span></span><span lang="EN-US"><span><span>EURONEXT</span></span></span><span lang="ZH-CN"><span><span>)上市(</span></span></span><span lang="EN-US"><span><span>IBA</span></span></span><span lang="ZH-CN"><span><span>:路透社</span></span></span><span lang="EN-US"><span><span>IBAB.BR </span></span></span><span lang="ZH-CN"><span><span>和彭博社</span></span></span><span lang="EN-US"><span><span> IBAB.BB</span></span></span><span lang="ZH-CN"><span><span>)。</span></span></span></span></span></span></p> <p><span><span><span><span lang="ZH-CN"><span><span>更多</span></span></span><span lang="ZH-CN"><span>信息</span></span><span lang="ZH-CN"><span>,请访问:</span></span><a href="http://www.iba-worldwide.com"><span><span><span>www.iba-worldwide.com</span></span></span></a></span></span></span></p> <p>&nbsp;</p> <p><span><span><span><strong><span lang="ZH-CN"><span>关于</span></span></strong><strong><span lang="EN-US"><span>SCK</span></span></strong><strong><span lang="EN-US"><span> CEN</span></span></strong></span></span></span></p> <p><span><span><span><span lang="EN-US"><span>CK </span></span><span lang="EN-US"><span>CEN</span></span><span lang="ZH-CN"><span>是比利时最大的研究中心之一</span></span><span lang="ZH-CN"><span>。其拥有</span></span><span lang="EN-US"><span> 850 </span></span><span lang="ZH-CN"><span>多名员工,每天都致力于核能的开发和和平应用。</span></span><span lang="EN-US"><span>SCK </span></span><span lang="EN-US"><span>CEN</span></span><span lang="ZH-CN"><span>的研究活动涉及三个部分</span></span><span lang="ZH-CN"><span>:核设施的安全、核医学的发展以及保护人员和环境免受电离辐射。</span></span><span lang="EN-US"><span>SCK </span></span><span lang="EN-US"><span>CEN</span></span><span lang="ZH-CN"><span>在全球得到认可</span></span><span lang="ZH-CN"><span>,并通过众多出版物和培训课程分享其知识,</span></span><span lang="ZH-CN"><span>以不断保持这一个卓越领域里的的人才</span></span><span lang="ZH-CN">储备</span><span lang="ZH-CN">。</span></span></span></span></p> <p><span><span><span><span lang="EN-US">更多信息,请访问</span><span lang="ZH-CN">:</span><a href="http://www.sckcen.be"><span>www.</span><span>sc</span><span>kcen.be</span></a></span></span></span></p> Read Full Press Release CN  
Read Full Press Release EN  
Read Full Press Release FR  
Read Full Press Release NL  
Share

news.more_news_title

-

IBA Business Update – Third Quarter 2022

Louvain-La-Neuve, Belgium, 17 November 2022 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter ending 30 September 2022. &nbsp; Group Overview Business operations continue to be strong, with good performance across all four business units Exceptional group order intake of EUR 260 million at 30 September for 2022 to date, compared to EUR 133 million for the first nine months of 2021, driven by strong performance across the business, particularly within Industrial Solutions Backlog remains high at EUR 1.2 billion and new tenders continue to progress internationally for all business units Strong balance sheet with (unaudited) net cash position of EUR 134 million (30 June 2022: 137 million) &nbsp; Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has continued to see solid performance in the third quarter across all business units, both in terms of contract wins, technological advances and supported by targeted value driving acquisitions. We have been especially pleased to see continued momentum in Industrial Solutions, with the business unit passing a key milestone of EUR 100 million order intake to date this year. Within proton therapy we are seeing market dynamics shifting favorably with demand building in all regions globally and resulting in IBA winning strategically significant, high-value contracts. Looking ahead, whilst some challenges remain, the strategies and investments we are making are positively impacting and we are confident in the longer-term performance of the Group, underpinned by a strong balance sheet that we will continue to utilize for investment in future growth.” &nbsp; Proton Therapy 24 projects ongoing in Proton Therapy, with nine Proteus®PLUS1 and 15 Proteus®ONE1 systems in progress An active global pipeline, highlighting the strength of proton therapy market across all geographies A total of 40 service contracts now generating recurring revenues globally IBA qualified as the only supplier for the second round of significant tender to provide ten proton therapy units across Spain Multi-year research collaboration signed with Fred Hutchinson Cancer Center and the University of Washington (UW), Seattle, for ConformalFLASH®2 Proton Therapy Collaboration agreement signed with Apollo Hospitals Enterprise Ltd (AHEL) The PROTECT-trial consortium enrolled the first patient in a trial investigating proton therapy in oesophageal cancer Other Accelerators (RadioPharma, Industrial) Other Accelerators continued to perform strongly in Q3, with eight new systems sold in the period. A total of 29 systems have been sold in the first nine months of 2022, compared to 23 for the same period last year Exceptional performance by Industrial Solutions, with the business reaching the milestone of EUR 100 million order intake to date Collaboration deal agreed with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China Agreement signed with NorthStar Medical Radioisotopes for two additional Rhodotron® electron beam accelerators for commercial production of radioisotopes Launched Pantera, a joint venture with SCK CEN to produce actinium-225, one of the most promising alpha-emitting radioisotopes to fight cancers Contract for the installation of an integrated radiopharmaceutical production facility in Georgia, signed post-period end Post-period, contract with Sweden Ghana Medical Centre signed for an IntegraLab® PLUS in Ghana &nbsp; Dosimetry Signed a strategic alliance for radiation therapy dosimetry solutions with ScandiDos A.B. (SDOS.ST) and made a minority investment in the company IBA’s dosimetry solutions were made compatible with Halcyon® and Ethos™ radiotherapy and adaptive therapy solutions, post-period end Expanded IBA’s myQA® iON technology into Radiation Therapy, post-period end &nbsp; Outlook IBA has continued to perform well across all business units in 2022 to date and this momentum is expected to persist for the remainder of the year and beyond. The pipeline remains highly active in all businesses, underpinning visibility for the period ahead. Whilst some supply chain and inflation related challenges remain, we are seeing gradual improvements and as a business, we continue to mitigate macroeconomic pressures. With an exceptionally strong balance sheet, we are continuing with our extensive investment plan to bolster our infrastructure, supply chain and logistics, reinforce our digital ambitions and continue to maintain our market-leading technology. Alongside this, we will look to seek value-enhancing opportunities to drive future sustainable growth. &nbsp; Financial calendar Full Year Results 2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23 March 2023 Business Update First Quarter 2023&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18 May 2023 General Assembly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14 June 2023 &nbsp; &nbsp; Proteus®PLUS and Proteus®ONE are brand names of Proteus 235 ConformalFLASH® is a registered brand of IBA’s Proton FLASH irradiation solution currently under research and development phase. &nbsp; &nbsp;
查看更多
-

IBA expands its activities in Sub-Saharan Africa and signs contract with Sweden Ghana Medical Centre for an IntegraLab® PLUS in Accra, Ghana

New contract to provide broader access to diagnostics in emerging markets &nbsp; Louvain-La-Neuve, Belgium, October 13, 2022 – IBA&nbsp;(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, today announces a new contract with Sweden Ghana Medical Centre (SGMC) for an IntegraLab® PLUS in Accra, Ghana. SGMC is a leading private cancer care center focused on providing the highest quality cancer treatment in West Africa. The contract marks IBA’s increasing presence in the region with operations in 21 countries. &nbsp; IntegraLab® PLUS is a fully integrated solution that combines equipment and services for establishing a radiopharmaceutical GMP production center, tailored to each customer’s specific needs. The contract includes the delivery of an IntegraLab® solution, consisting of the installation and integration of a Cyclone® KIUBE 100 with Synthera® Extension, Synthera®+ HPLC and IFP loader. Sweden Ghana Medical Center will benefit from IBA's expertise for the complete setting-up of its radiopharmacy. &nbsp; This contract follows several others signed in Tanzania and South Africa, and further highlights IBA’s ambition to broaden access to cancer diagnostics and treatments in regions of the world with low population density and limited access to healthcare. The demand for diagnostic and therapeutic equipment in Africa is rapidly growing, with cancer cases rising to over 800 000 cases*&nbsp;per year in Sub-Saharan Africa. &nbsp; This latest announcement follows IBA’s launch of the Cyclone® KEY in January this year, which will provide more widespread global access to diagnostic solutions in oncology, neurology and cardiology as it answers a demand from the African market for a compact radiopharmaceuticals production solution. &nbsp; Olivier Legrain, Chief Executive Officer at IBA, commented:&nbsp;“This contract marks an important milestone for IBA as we expand the use of our technology into emerging markets such as Africa. Continued innovation from our RadioPharma Solutions Business Unit is vital to providing patients with access to much needed diagnostics and treatments, something that is core to IBA’s mission and reinforced by the continued development of our technology. We look forward to working with SGMC and to helping them to achieve their mission of being at the forefront of cancer care in Africa.” &nbsp; Dr. Clement Edusa, CEO and Medical Director at Sweden Ghana Medical Centre, added: “At SGMC, our vision is to provide the best possible cancer care across West Africa. The IntegraLab® will allow us to provide the most innovative diagnostic imaging tests to our patients, with the hope that we can identify disease and therefore start an appropriate course of treatment much quicker. IBA’s technology, not only provides us with a cost efficient and user-friendly cyclotron system but&nbsp;also tailored solutions that meet our specific needs, allowing us to provide the best possible care to our patients.” &nbsp; *https://gco.iarc.fr/today/data/factsheets/populations/971-sub-saharan-africa-hub-fact-sheets.pdf
查看更多